142 related articles for article (PubMed ID: 19884395)
1. Tongue hyperpigmentation resulting from peginterferon alfa and ribavirin combination therapy: a case report.
de Moraes PC; Noce CW; Thomaz LA; Mautoni MC; Corrêa ME
J Am Dent Assoc; 2009 Nov; 140(11):1377-9. PubMed ID: 19884395
[TBL] [Abstract][Full Text] [Related]
2. Tongue hyperpigmentation resulting from peginterferon alfa-2b and ribavirin treatment in a patient with chronic hepatitis C.
Ghosh S; Duseja A; Dhiman RK; Chawla YK
Dig Dis Sci; 2012 Mar; 57(3):820-1. PubMed ID: 21948358
[TBL] [Abstract][Full Text] [Related]
3. Tongue hyperpigmentation in a caucasian patient coinfected with HIV and hepatitis C during peginterferon alfa-2b and ribavirin therapy.
Torres HA; Bull L; Arduino RC; Barnett BJ
Am J Gastroenterol; 2007 Jun; 102(6):1334-5. PubMed ID: 17531028
[No Abstract] [Full Text] [Related]
4. Lingual hyperpigmentation with pegylated interferon and ribavirin therapy in patients with chronic hepatitis C.
Sood A; Midha V; Bansal M; Goyal A; Sharma N
Indian J Gastroenterol; 2006; 25(6):324. PubMed ID: 17264447
[No Abstract] [Full Text] [Related]
5. Tongue hyperpigmentation during hepatitis C treatment.
Bachmeyer C; Pellen JC
CMAJ; 2012 Sep; 184(13):1498. PubMed ID: 22451683
[No Abstract] [Full Text] [Related]
6. Lingual hyperpigmentation from pegylated interferon and ribavirin treatment of hepatitis C.
Farshidi D; Chiu MW
J Am Acad Dermatol; 2010 Jan; 62(1):164-165. PubMed ID: 20082904
[No Abstract] [Full Text] [Related]
7. Tongue hyperpigmentation during interferon-alpha and ribavirin therapy.
Aguayo-Leiva I; Pérez B; Salguero I; Jaén P
Eur J Dermatol; 2009; 19(3):291-2. PubMed ID: 19286489
[No Abstract] [Full Text] [Related]
8. Secondary hyperpigmentation during interferon alfa treatment for chronic hepatitis C virus infection.
Tsilika K; Tran A; Trucchi R; Pop S; Anty R; Cardot-Leccia N; Lacour JP; Ortonne JP; Passeron T
JAMA Dermatol; 2013 Jun; 149(6):675-7. PubMed ID: 23553009
[TBL] [Abstract][Full Text] [Related]
9. What caused this lingual hyperpigmentation in a patient with chronic hepatitis C?
Radha Krishna Y; Itha S
Liver Int; 2010 Mar; 30(3):416. PubMed ID: 19422481
[No Abstract] [Full Text] [Related]
10. A surprising hyperpigmentation of the gums and tongue.
Dell'Isola S; Ialungo AM; Starnini G; Roselli P; Ghittoni G; Caturelli E
Gut; 2008 Dec; 57(12):1697, 1727. PubMed ID: 19022927
[No Abstract] [Full Text] [Related]
11. Tongue hyperpigmentation during interferon therapy.
Karabay O; Goksugur N; Ogutlu A
J Dermatol; 2011 Mar; 38(3):290-1. PubMed ID: 21342236
[No Abstract] [Full Text] [Related]
12. Hyperpigmentation during interferon-alpha therapy for chronic hepatitis C virus infection.
Willems M; Munte K; Vrolijk JM; Den Hollander JC; Böhm M; Kemmeren MH; De Man RA; Brouwer JT
Br J Dermatol; 2003 Aug; 149(2):390-4. PubMed ID: 12932249
[TBL] [Abstract][Full Text] [Related]
13. Tongue and skin hyperpigmentation during PEG-interferon-alpha/ribavirin therapy in dark-skinned non-Caucasian patients with chronic hepatitis C.
Gurguta C; Kauer C; Bergholz U; Formann E; Steindl-Munda P; Ferenci P
Am J Gastroenterol; 2006 Jan; 101(1):197-8. PubMed ID: 16405555
[TBL] [Abstract][Full Text] [Related]
14. Tongue hyperpigmentation during PEG-interferon-alfa/ribavirin therapy in a non-Caucasian patient with chronic hepatitis C: a case report and review of the literature.
Mlika RB; Kerkeni N; Marrak H; Fenniche S; Mokhtar I; Debbiche A
Int J Dermatol; 2013 May; 52(5):643-4. PubMed ID: 23046405
[No Abstract] [Full Text] [Related]
15. R1626 plus peginterferon Alfa-2a provides potent suppression of hepatitis C virus RNA and significant antiviral synergy in combination with ribavirin.
Pockros PJ; Nelson D; Godofsky E; Rodriguez-Torres M; Everson GT; Fried MW; Ghalib R; Harrison S; Nyberg L; Shiffman ML; Najera I; Chan A; Hill G
Hepatology; 2008 Aug; 48(2):385-97. PubMed ID: 18570306
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of pegylated interferon alfa-2b and ribavirin combination therapy versus pegylated interferon monotherapy in hemodialysis patients: a comparison of 2 sequentially treated cohorts.
Tseng PL; Chen TC; Chien YS; Hung CH; Yen YH; Chang KC; Tsai MC; Lin MT; Lee CT; Shen CH; Hu TH
Am J Kidney Dis; 2013 Oct; 62(4):789-95. PubMed ID: 23746377
[TBL] [Abstract][Full Text] [Related]
17. Peginterferon alfa-2a plus ribavirin for the treatment of dual chronic infection with hepatitis B and C viruses.
Liu CJ; Chuang WL; Lee CM; Yu ML; Lu SN; Wu SS; Liao LY; Chen CL; Kuo HT; Chao YC; Tung SY; Yang SS; Kao JH; Liu CH; Su WW; Lin CL; Jeng YM; Chen PJ; Chen DS
Gastroenterology; 2009 Feb; 136(2):496-504.e3. PubMed ID: 19084016
[TBL] [Abstract][Full Text] [Related]
18. [Lingual hyperpigmentation in a patient with chronic infection].
López Peláez MV; González Díaz P; Téllez Molina MJ; Vergas García J
Enferm Infecc Microbiol Clin; 2013 Apr; 31(4):264-5. PubMed ID: 23260387
[No Abstract] [Full Text] [Related]
19. Falsely low hemoglobin A1c levels in a patient receiving ribavirin and peginterferon alfa-2b for hepatitis C.
Gross BN; Cross LB; Foard JC; Wood YA
Pharmacotherapy; 2009 Jan; 29(1):121-3. PubMed ID: 19113800
[TBL] [Abstract][Full Text] [Related]
20. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection.
Fried MW; Shiffman ML; Reddy KR; Smith C; Marinos G; Gonçales FL; Häussinger D; Diago M; Carosi G; Dhumeaux D; Craxi A; Lin A; Hoffman J; Yu J
N Engl J Med; 2002 Sep; 347(13):975-82. PubMed ID: 12324553
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
